Enzo Biochem — Proxy Contest (December 2015)
63 slides from Enzo Biochem's proxy contest presentation, Dec 17, 2015
Slide 1: Presentation to ISS December 2015
LO ONE N E STS A TAR RVAVLA UEL UM E AINA N VGEEME S T ONRTS L LLC P Presentation to ISS December 2015
Slide 2: Disclaimer
Disclaimer THIS PRESENTATION IS FOR DISCUSSION AND GENERAL INFORMATIONAL PURPOSES ONLY. IT DOES NOT HAVE REGARD TO THE SPECIFIC INVESTMENT OBJECTIVE, FINANCIAL SITUATION, SUITABILITY, OR THE PARTICULAR NEED OF ANY SPECIFIC PERSON WHO MAY RECEIVE THIS PRESENTATION, AND SHOULD NOT BE TAKEN AS ADVICE O
Slide 3: It Is Time for Change at Enzo Biochem
It Is Time for Change at Enzo Biochem • We believe change is warranted and necessary as a result of: 1. Stock Price Underperformance: Over the past 10 fiscal years, Enzo’s Total Shareholder Return (TSR) has been negative and has drastically underperformed all relevant peer groups and US Equity indic
Slide 4: Table of Contents
Table of Contents Executive Summary, Who We Are, & Our Plan 4 Lone Star Value Nominees: Relevant Experience 40 and Qualifications Enzo Shareholder Return Underperformed 11 Conclusion 46 Peers & Indices History of Poor Financial Performance 19 Appendix 48 • Performance Statistics • Digirad Case Study
Slide 5: Executive Summary
Executive Summary • LSV is a long-term Enzo shareholder: we began researching Enzo in 2013 and started purchasing shares in September 2013; our research indicates that the Company is undervalued, but the incumbent Board seems unwilling or unable to generate operating profits and improve corporate go
Slide 6: Executive Summary (cont.)
Executive Summary (cont.) • Enzo’s Board has strongly resisted fresh perspective despite a decade of financial losses, questionable related party transactions, and extremely anti-shareholder corporate governance policies • We believe the incumbent Board lacks significant independence considering two
Slide 7: Why We Believe Enzo Has Potential
Why We Believe Enzo Has Potential • Enzo’s underlying business has significant potential, but lacks execution ― LSV’s nominees have no intention of changing Enzo’s core business model, but will focus on cost control and profitability o This process should not in any way disrupt the hard work of Enzo
Slide 8: Lone Star's Engagement with Enzo
Lone Star’s Engagement with Enzo • September 19, 2013 – Jeff Eberwein, CEO of LSV, met with Barry Weiner at Enzo’s headquarters to discuss the Company’s background and IP litigation strategy. Mr. Eberwein inquired about Enzo’s high operating expenses, history of losses, related party transactions, p
Slide 9: Lone Star Value – Who We Are
Lone Star Value – Who We Are • Lone Star Value is a deep value-oriented investment firm focused on small-cap opportunities with a long-term focus on realizing returns via constructive engagement with its portfolio companies in order to maximize shareholder value ― As a last resort, LSV will run a pr
Slide 10: Our Plan
Our Plan If elected, our nominees will seek to do the following: 1. Immediately add value to Enzo’s operational and financial performance Examine overhead (SG&A) expenses to remove unnecessary expenditures Examine R&D expenditures to focus on high Return on Investment (ROI) projects Instill a
Slide 11: Lone Star's Settlement Offer
Lone Star’s Settlement Offer • LSV has nominated two highly-qualified and value-adding directors to the Company’s current Board ― In order to avoid a proxy contest, LSV offered an amicable resolution of one Board addition without a proxy fight, removal of any incumbent directors, or Enzo having to i
Slide 12: Enzo Shareholder Return Underperformed vs. Peers & Indices
Enzo Shareholder Return Underperformed vs. Peers & Indices PAGE 11
Slide 13: Enzo's Seemingly Arbitrary and Self-Serving Choices of Various Peer Groups
Enzo’s Seemingly Arbitrary and Self-Serving Choices of Various Peer Groups • Over the last year, Enzo has compared itself to 3 different peer groups, raising serious questions about Enzo’s peer group selection practices 1. Enzo’s self-selected peer group for its 2014 Annual Meeting(1) consisted of 1
Slide 14: No matter which peer group you choose, Enzo has underperformed
Enzo’s Seemingly Arbitrary and Self-Serving Choices of Various Peer Groups Peer Group Average Returns(1) Revenue Market Cap Peer Group 1-Yr Return 3-Yr Return 5-Yr Return 10-Yr Return ($ millions) ($ millions) 2014 Proxy Peer $418.4 $4,428.8 13.8% 161.5% 195.7% 354.0% Group Average 2015 Proxy Peer $
Slide 15: Growth of $100: Enzo vs. 2014 Proxy Peers
Enzo vs. 2014 Proxy Peers • Enzo’s total stock price performance has underperformed its 2014 proxy peers by approximately 193% over the last 5 years Stock Price Performance: Enzo vs. 2014 Proxy Peer Group(1) 350 Enzo 2014 Proxy Peer Group 300 250 Growth of $100 200 150 100 50 - (1) Source: Enzo’s De
Slide 16: Growth of $100: Enzo vs. 2015 Amended Proxy Peers
Enzo vs. 2015 Amended Proxy Peers • Enzo’s total stock price performance has underperformed its 2015 proxy peers by approximately 73% over the last 5 years Stock Price Performance: Enzo vs. 2015 Proxy Peer Group(1) 250 Enzo 2015 Proxy Peer Group 200 Growth of $100 150 100 50 - (1) Source: Amended 10
Slide 17: Growth of $100: Enzo vs. December 2015 Proxy Contest Peers
Enzo vs. December 2015 Proxy Contest Peers • Enzo’s total stock price performance has underperformed its December 2015 Proxy Contest Peers by approximately 90% over the last 5 years Stock Price Performance: Enzo vs. December 2015 Proxy Contest Peer Group(1) 250 Enzo December 2015 Proxy Contest Peer
Slide 18: Growth of $100: Enzo vs. ISS-Selected Peers
Enzo vs. ISS-Selected Peers • Enzo’s total stock price performance has underperformed its ISS peer group by approximately 207% over the last 5 years and has underperformed the Russell 3000 and MSCI Life Science Tools & Services Indices by approximately 72% and 114% respectively Stock Price Performan
Slide 19: Enzo vs. Peers: Stock Price Underperformance
Enzo vs. Peers: Stock Price Underperformance • Enzo’s stock price has underperformed its self-selected and ISS peer groups over the past 1-,3-, 5-, and 10-year periods • We believe this underperformance is a direct result of the Board and management team’s failure to generate profitability for its s
Slide 20: History of Poor Financial Performance
History of Poor Financial Performance PAGE 19
Slide 21: Enzo's Declining Profitability
Enzo’s Declining Profitability • Enzo’s gross margin has fallen from 66% in fiscal year 2005 to only 44% in fiscal year 2015 Gross Margin(1) 70% 65% 60% 55% 50% 45% 40% 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 (1) Source: Bloomberg; as of 11/30/2015. PAGE 20
Slide 22: Enzo vs. Peers: Operating Margin
Enzo vs. Peers: Operating Margin • Enzo’s profitability has been consistently negative over the past 10 years, and has significantly underperformed its peers ― We believe Enzo’s underperformance is directly related to the Board and management team’s inability to effectively control costs and generat
Slide 23: Cumulative 10-year Net Operating Losses of $168mm
Enzo’s Historical Financial Performance • Despite revenue growth since fiscal year 2005, Enzo has somehow failed to generate a profit in any given fiscal year since 2005, which we believe is at least partially due to excessive SG&A expenses ― In a meeting with Mr. Eberwein on September 19, 2013, Enz
Slide 24: Enzo's Historical Financial Performance (cont.)
Enzo’s Historical Financial Performance (cont.) Revenue Net Income 120 100 80 60 $ (Millions) 40 20 - (20) (40) (60) (1) (2) 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 (1) Adjusted FY2014 non-GAAP net income figure as reported in Enzo’s Q4 2014 Earnings Press Release as adjusted for lega
Slide 25: Excessive Corporate Expenses (SG&A)
Excessive Corporate Expenses (SG&A) • As revenue has more than doubled over the last 10 years, SG&A expenses have as well ― We believe this exemplifies management’s inability to scale its operations and control costs ― In addition, on the Company’s recent Q1 2016 earnings call, Mr. Weiner stated tha
Slide 26: Poor Corporate Governance, Shareholder Frustration, & Related Party Transactions
Poor Corporate Governance, Shareholder Frustration, & Related Party Transactions PAGE 25
Slide 27: Poor Corporate Governance Practices
Poor Corporate Governance Practices • We believe Enzo’s incumbent Board has entrenched themselves through severe limitations on shareholder rights ― Classified Board o In our view, the ability of shareholders to select directors each year is an important check on the performance of the Board and is
Slide 28: Related Party Transactions – extremely troubling to LSVM
Related Party Transactions – extremely troubling to LSVM • Enzo Labs, a subsidiary of the Company, leases a facility in Farmingdale, New York from Pari Management Corporation (“Pari”), which is owned equally by Dr. Elazar Rabbani, Barry Weiner (and his wife), and former officer and director Shahram
Slide 29: Related Party Transactions (cont.)
Related Party Transactions (cont.) • The chart below lists the lease payments made by Enzo Labs to Pari on an annual basis, as disclosed in the Company’s annual proxy statement filings (1) Source: Enzo’s annual proxy statement filings. (2) Source: The United States Social Security Administration. (3
Slide 30: We Believe Enzo's Nominees Lack Relevant Experience and Question Dov Perlysky's Membership on the Board
We Believe Enzo’s Nominees Lack Relevant Experience and Question Dov Perlysky’s Membership on the Board • Gregory M. Bortz – Independent Director ― Financial background in investment banking and private equity; director since January 2010; no healthcare or IP litigation experience ― Mr. Bortz has no
Slide 31: How "Independent" is Mr. Perlysky?
How “Independent” is Mr. Perlysky? • Dov Perlysky and his family have a long, intertwined history with Enzo. How “independent” is Mr. Perlysky? ― In addition, he has a history of serving on extremely poorly performing “penny stock” boards D.H. Blair J. Morton Davis (“Morty”) Rosalind Davidowitz Foun
Slide 32: Incumbent Directors Inadequate Public Board Experience & Abysmal Track Record
Incumbent Directors Inadequate Public Board Experience & Abysmal Track Record • The tables below show Enzo’s three “independent” directors’ external public board experience and lack of credibility: Return During Dov Perlysky Ticker Market Cap ($mm) Tenure Filing Compliance Pharma-Bio Serv, Inc. PBSV
Slide 33: Dov Perlysky's Abysmal Track Record: Engex
Dov Perlysky’s Abysmal Track Record • Engex has declined -82% since Mr. Perlysky joined its board Engex, Inc. (EXGI)(1) $60 $50 $40 $30 $20 $10 $- (1) Chart source: Bloomberg; as of 11/30/2015; Mr. Perlysky’s tenure spans from 01/18/2000 to present. PAGE 32
Slide 34: Dov Perlysky's Abysmal Track Record: Pharma-Bio Serv
Dov Perlysky’s Abysmal Track Record (Cont’d) • Pharma-Bio Serv has declined -28% since Mr. Perlysky joined its board $2.50 Pharma-Bio Serv, Inc. (PBSV)(1) $2.00 $1.50 $1.00 $0.50 $- (1) Chart source: Bloomberg; as of 11/30/2015; Mr. Perlysky’s tenure spans from 12/04/2006 to present. PAGE 33
Slide 35: Dov Perlysky's Abysmal Track Record: Oak Tree Education Partners
Dov Perlysky’s Abysmal Track Record (Cont’d) • Oak Tree Education Partners stock has declined -80% since Mr. Perlysky joined its board Oak Tree Educational Partners, Inc. (OTED)(1) $4.50 THIS MICROCAP “PENNY STOCK” HAS NOT TRADED SINCE SEPTEMBER 2013: $4.00 $3.50 $3.00 $2.50 $2.00 $1.50 $1.00 $0.50
Slide 36: Dov Perlysky's Abysmal Track Record: Highlands Bancorp
Dov Perlysky’s Abysmal Track Record (Cont’d) • Highlands Bancorp has declined -11% since Mr. Perlysky joined its board $10 Highlands Bancorp, Inc. (HSBK)(1) $9 $8 $7 $6 $5 $4 $3 $2 $1 $- (1) Chart source: Bloomberg; as of 11/30/2015; Mr. Perlysky’s tenure spans from 12/05/2007 to present. PAGE 35
Slide 37: Dov Perlysky's Abysmal Track Record: News Communications
Dov Perlysky’s Abysmal Track Record (Cont’d) • News Communications is the only publicly traded company that has increased in share price since Mr. Perlysky joined its board HOWEVER, THIS MICROCAP “PENNY STOCK” APPEARS TO HAVE TRADED ON ONLY 28(1) DAYS SINCE 2007 AND HAS NOT TRADED SINCE MAY 2015: Ne
Slide 38: Mr. Kasten's Abysmal Track Record: GeneLink
Mr. Kasten’s Abysmal Track Record • GeneLink has declined -99% since Dr. Kasten joined its board $0.60 GeneLink, Inc. (GNLKQ)(1) GENELINK HAS FILED FOR BANKRUPTCY: $0.50 $0.40 $0.30 $0.20 $0.10 $- (1) Chart source: Bloomberg; as of 11/30/2015; Mr. Kasten’s tenure spans from 02/28/2007 to present. PA
Slide 39: Mr. Kasten's Abysmal Track Record: Cleveland BioLabs
Mr. Kasten’s Abysmal Track Record (Cont’d) • Cleveland BioLabs declined -90% during Dr. Kasten’s tenure on its board $300 Cleveland BioLabs, Inc. (CBLI)(1) $250 $200 $150 $100 $50 $- (1) Chart source: Bloomberg; Mr. Kasten’s tenure spans from 07/31/2006 to 06/14/2013. PAGE 38
Slide 40: Mr. Kasten's Abysmal Track Record: Siga Technologies
Mr. Kasten’s Abysmal Track Record (Cont’d) • Siga Technologies declined -6% during Dr. Kasten’s tenure on its board $3 Siga Technologies, Inc. (SIGAQ)(1) SIGA TECHNOLOGIES HAS SINCE FILED FOR BANKRUPTCY: $2 $1 $- (1) Chart source: Bloomberg; Mr. Kasten’s tenure spans from 05/29/2003 to 04/03/2006. P
Slide 41: Lone Star Value Nominees: Relevant Experience and Qualifications
Lone Star Value Nominees: Relevant Experience and Qualifications PAGE 40
Slide 42: Lone Star Value Board Nominees
Lone Star Value Board Nominees • Angelis and Climaco bring a range of highly relevant experience, complementary skills, and deep knowledge in healthcare and finance, including expertise in: Healthcare, IP Litigation, Public Board Experience, Cost Control, Restructuring/Turnaround, and M&A Lone Star
Slide 43: Angelis and Climaco: Truly Independent Nominees
Angelis and Climaco: Truly Independent Nominees • Enzo uses the criteria listed below to determine if a nominee is independent, and both of LSV’s nominees qualify as independent by Enzo’s standards (NYSE criteria to be an Independent Director) Dimitrios John Enzo’s Independent Director Criteria Ange
Slide 44: Nominee Biography: Dimitrios J. Angelis
Nominee Biography: Dimitrios J. Angelis Dimitrios J. Angelis – Accomplished Executive • We believe Mr. Angelis’ healthcare, technology, and turnaround experience will make him a valuable addition to the Board • Mr. Angelis currently serves as Executive Counsel at Life Sciences Law Group, which provi
Slide 45: Nominee Biography: John M. Climaco, Esq.
Nominee Biography: John M. Climaco, Esq. John M. Climaco, Executive Vice President of Perma-Fix Medical S.A. • We believe Mr. Climaco's significant executive and public board experience, coupled with his vast healthcare and biotech experience will instantly add value and knowledge to the Enzo Board
Slide 46: John M. Climaco — A Turnaround and Restructuring Expert
John M. Climaco — A Turnaround and Restructuring Expert • Mr. Climaco has years of experience advising companies in difficult financial situations • Mr. Climaco specializes in restructuring and turnaround management for financially challenged companies • Mr. Climaco has been specifically brought in
Slide 47: Conclusion
| * LONE STAR VALUE — MANAGEMENT Conclusion PAGE 46
Slide 48: Conclusion
Conclusion • We do not believe Enzo’s incumbent Board will take the necessary steps to enhance shareholder value or shareholder rights ― Enzo’s incumbent Board has demonstrated unwillingness or inability to improve shareholder value or its poor corporate governance practices, including by refusing t
Slide 49: Appendix
STRICTLY CONFIDENTIAL A P P E N D I X PAGE 48
Slide 50: Stock Price Underperformance vs. Enzo's 2014 Proxy Peers
Stock Price Underperformance vs. Enzo’s 2014 Proxy Peers Total Shareholder Return (1) 1-Yr 3-Yr 5-Yr 10-Yr AFFYMETRIX INC AFFX 3.7% 184.4% 127.6% -80.8% ALKERMES PLC ALKS 33.3% 279.9% 600.0% 303.5% CEPHEID INC CPHD -34.7% 10.9% 82.5% 227.0% CRYOLIFE INC CRY 8.8% 90.4% 101.4% 198.9% GENOMIC HEALTH IN
Slide 51: Stock Price Underperformance vs. Enzo's 2015 Proxy Peers
Stock Price Underperformance vs. Enzo’s 2015 Proxy Peers Total Shareholder Return (1) 1-Yr 3-Yr 5-Yr 10-Yr ADAMAS PHARMACEUTICALS INC ADMS 8.7% AFFYMETRIX INC AFFX 3.7% 184.4% 127.6% -80.8% AMAG PHARMACEUTICALS INC AMAG -28.4% 77.1% 69.7% 152.6% ARRAY BIOPHARMA INC ARRY -1.7% 1.3% 23.4% -41.1% CTI B
Slide 52: Stock Price Underperformance vs. Enzo's ISS Peers
Stock Price Underperformance vs. Enzo’s ISS Peers Total Shareholder Return (1) 1-Yr 3-Yr 5-Yr 10-Yr AMAG PHARMACEUTICALS INC AMAG -28.4% 77.1% 69.7% 152.6% BIOTELEMETRY INC BEAT 27.8% 481.1% 212.1% HARVARD BIOSCIENCE INC HBIO -35.6% 5.9% 6.4% 8.3% NEOGENOMICS INC NEO 88.0% 180.6% 527.6% 3271.8% PACI
Slide 53: Stock Price Underperformance vs. Enzo's December 2015 Proxy Contest Peers
Stock Price Underperformance vs. Enzo’s December 2015 Proxy Contest Peers Total Shareholder Return (1) 1-Yr 3-Yr 5-Yr 10-Yr GENOMIC HEALTH INC GHDX -8.8% 9.6% 64.3% 228.9% NEOGENOMICS INC NEO 88.0% 180.6% 527.6% 3271.8% SONIC HEALTHCARE LTD SHL 21.7% 74.1% 121.8% 126.5% NATERA INC NTRA VERACYTE INC
Slide 54: Operating Underperformance vs. Enzo's 2014 Proxy Peers
Operating Underperformance vs. Enzo’s 2014 Proxy Peers Operating Margin(1) 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 5-Yr Average 10-Yr Average AFFYMETRIX INC AFFX 18% -1% 6% 11% -10% -2% -6% -13% -4% 1% -5% 0% ALKERMES PLC ALKS -80% 8% 5% 6% 41% -24% -24% -23% 6% -14% -16% -10% CEPHEID INC
Slide 55: Operating Underperformance vs. Enzo's 2015 Proxy Peers
Operating Underperformance vs. Enzo’s 2015 Proxy Peers Operating Margin(1) 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 5-Yr Average 10-Yr Average ADAMAS PHARMACEUTICALS INC ADMS 53% 80% 33% 56% 56% AFFYMETRIX INC AFFX 18% -1% 6% 11% -10% -2% -6% -13% -4% 1% -5% 0% AMAG PHARMACEUTICALS INC AMAG
Slide 56: Operating Underperformance vs. Enzo's 2015 Proxy Peers
Operating Underperformance vs. Enzo’s 2015 Proxy Peers Operating Margin(1) 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 5-Yr Average 10-Yr Average GENOMIC HEALTH INC GHDX -622% -106% -46% -16% -6% 2% 4% 4% -5% -9% -1% -80% NEOGENOMICS INC NEO -4% -6% -9% -1% 2% 5% 3% 0% -1% SONIC HEALTHCARE LTD
Slide 57: Operating Underperformance vs. Enzo's ISS Peers
Operating Underperformance vs. Enzo’s ISS Peers Operating Margin vs. ISS Peer Group (1) 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 5-Yr Average 10-yr Average AMAG PHARMACEUTICALS INC AMAG -537% -1006% -1661% -4108% -570% -125% -130% -20% -14% -3% -59% -818% BIOTELEMETRY INC BEAT -13% 0% 12% -
Slide 58: Digirad Corp (DRAD) Case Study
Digirad Corp (DRAD) Case Study • Digirad is a leader in the nuclear imaging industry ― Digirad is the only publicly-traded U.S. company that provides mobile, on-site nuclear imaging services to physicians • LSV’s Jeff Eberwein joined Digirad’s board in April 2012 and was named Head of the Strategy C
Slide 59: Digirad Timeline
Digirad Timeline $7.00 October 14, 2015 DRAD acquires DMS Health $6.00 February 7, 2013 Technologies Two incumbent Directors resign; Eberwein named Chairman; Climaco March 14, 2014 named Head of Strategy DRAD acquires Committee Telerhythmics $5.00 December 31, 2012 DRAD acquires Doctors4Doctors $4.0
Slide 60: Hudson Global, Inc. (HSON) Case Study
Hudson Global, Inc. (HSON) (“Hudson”) Case Study • In May 2014, LSV won a proxy contest for two board seats in a vote of 80-6 • Within one year, Hudson’s corporate governance was substantially improved by: ― Fully declassifying its board of directors, resulting in all directors standing for annual e
Slide 61: Lone Star Value's Engagement with Enzo: Timeline of Events
Lone Star Value’s Engagement with Enzo Timeline of Events Jeffrey Eberwein, CEO of Lone Star Value, met with Barry Weiner, Enzo’s President, CFO, co-founder, and a Director, at the Company’s HQ on Madison Avenue in New York to discuss the Company’s history, business, and its Intellectual Property (“
Slide 62: Lone Star Value's Engagement with Enzo: Timeline of Events
Lone Star Value’s Engagement with Enzo Timeline of Events Mr. Eberwein had a call with Mr. Weiner to discuss LSV’s director nominations and the value Mr. Climaco and Mr. Angelis could add to the Board for the benefit of all Enzo shareholders. Mr. Weiner expressed his displeasure with October 1st, 20
Slide 63: Investor Contact Information
Investor Contact Information John Glenn Grau InvestorCom Email: jgrau@investor-com.com Office: +1.203.972.9300 ext. 11 Lone Star Value Management, LLC 53 Forest Avenue First Floor Old Greenwich, CT 06870 PAGE 62